
Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.
The month in review spotlights perspectives on collaborative GI care, updates in C diff, and new research about disorders of gut brain interaction.
June proved to be a dynamic month in






